CORC

在结果中检索

CORC

浏览/检索结果: 共40条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor 期刊论文
THORACIC CANCER, 2022
作者:  Wang, Wenxian;  Wang, Qian;  Xu, Chunwei;  Li, Ziming;  Song, Zhengbo
收藏  |  浏览/下载：32/0  |  提交时间：2022/12/23
Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China 期刊论文
THORACIC CANCER, 2022
作者:  Xu, Chunwei;  Si, Lu;  Wang, Wenxian;  Li, Ziming;  Song, Zhengbo
收藏  |  浏览/下载：36/0  |  提交时间：2022/12/22
SVD based scale transform invariant observable degree for LTI system 期刊论文
SCIENCE CHINA-INFORMATION SCIENCES, 2020, 卷号: 64, 期号: 3, 页码: 3
作者:  Ge, Quanbo;  Zhuo, Peng;  He, Hongli;  Hu, Zhentao;  Duan, Zhansheng
收藏  |  浏览/下载：24/0  |  提交时间：2020/06/22
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 期刊论文
JOURNAL OF HEPATOLOGY, 2019, 卷号: 70
作者:  Gong, Guozhong;  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun
收藏  |  浏览/下载：57/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：46/0  |  提交时间：2019/12/05
NKT Cells in Mice Originate from Cytoplasmic CD3-Positive, CD4-CD8- Double-Negative Thymocytes that Express CD44 and IL-7Rα. 期刊论文
Scientific reports, 2019, 卷号: 9, 页码: 1874
作者:  Hu Zhansheng;  Gu Wen;  Wei Yang;  Liu Gang;  Wu Shengli
收藏  |  浏览/下载：8/0  |  提交时间：2019/11/19
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：36/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  
收藏  |  浏览/下载：38/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：32/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：30/0  |  提交时间：2019/12/05

©版权所有 ©2017 CSpace - Powered by CSpace